Acute Lymphoblastic Leukemia(ALL)

DrugDrug NameDrug Description
DB14730Calaspargase pegolAsparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) [A40270]. Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparaginase treatment in ALL [A40270], [A40273], [F2432]. Calaspargase pegol, also known as _asparlas_, is an asparagine specific enzyme which is indicated as a part of a multi-agent chemotherapy regimen for the treatment of ALL [L4890]. The asparagine specific enzyme is derived from Escherichia coli, as a conjugate of L-asparaginase (L-asparagine amidohydrolase) and monomethoxypolyethylene glycol (mPEG) with a succinimidyl carbonate (SC) linker to create a stable molecule which increases the half-life and decreases the dosing frequency [FDA label], [A40270]. Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) [L4890].
DrugDrug NameTargetType
DB14730Calaspargase pegolL-asparaginetarget
DrugDrug NamePhaseStatusCount